mutLBSgeneDB |
Gene summary for BRD4 |
![]() |
Basic gene Info. | Gene symbol | BRD4 |
Gene name | bromodomain containing 4 | |
Synonyms | CAP|HUNK1|HUNKI|MCAP | |
Cytomap | UCSC genome browser: 19p13.1 | |
Type of gene | protein-coding | |
RefGenes | NM_014299.2, NM_058243.2, | |
Description | bromodomain-containing 4bromodomain-containing protein 4chromosome-associated protein | |
Modification date | 20141222 | |
dbXrefs | MIM : 608749 | |
HGNC : HGNC | ||
Ensembl : ENSG00000141867 | ||
HPRD : 10574 | ||
Vega : OTTHUMG00000183252 | ||
Protein | UniProt: O60885 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_BRD4 | |
BioGPS: 23476 | ||
Pathway | NCI Pathway Interaction Database: BRD4 | |
KEGG: BRD4 | ||
REACTOME: BRD4 | ||
Pathway Commons: BRD4 | ||
Context | iHOP: BRD4 | |
ligand binding site mutation search in PubMed: BRD4 | ||
UCL Cancer Institute: BRD4 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0006338 | chromatin remodeling | 23728299 | GO:0032968 | positive regulation of transcription elongation from RNA polymerase II promoter | 19103749 | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 19103749 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 23086925 | GO:0050727 | regulation of inflammatory response | 19103749 | GO:1901407 | regulation of phosphorylation of RNA polymerase II C-terminal domain | 23086925 |
Top |
Ligand binding site mutations for BRD4 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | V90,D88 | A89V | COAD | 1 | M425 | F426L | GBM | 1 | I393 | I394M | HNSC | 1 | P375 | P375L | SKCM | 1 | P95 | P95T | SKCM | 1 | D96 | D96N | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for BRD4 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | P375 | P375L | 0.038494297 | I393 | I394M | -1.7103471 | P95 | P95T | -1.4355776 | D96 | D96N | -1.1169378 | M425 | F426L | -0.58041424 | D88 | A89V | -0.50923202 | V90 | A89V | -0.50923202 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for BRD4 |
![]() |
![]() |
Top |
Top |
Phenotype information for BRD4 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for BRD4 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 25V | N-[3-(2-METHYL-1-OXIDOQUINOLIN-4-YL)PHENYL]ACETAMIDE | 4meo | A | D88 | 2R4 | NU7441 | 8-(DIBENZO[B,D]THIOPHEN-4-YL)-2-(MORPHOLIN-4-YL)-4H- CHROMEN-4-ONE | 4o72 | A | D88 | WSH | BENZYL [(4R)-1-METHYL-6-PHENYL-4H-[1,2,4]TRIAZOLO[4,3-A][1,4]BENZODIAZEPIN-4-YL]CARBAMATE | 2yem | A | P375 | WSH | BENZYL [(4R)-1-METHYL-6-PHENYL-4H-[1,2,4]TRIAZOLO[4,3-A][1,4]BENZODIAZEPIN-4-YL]CARBAMATE | 2yem | B | P375 | 4LD | 1-(3-CYCLOPROPYL-5-METHYL-1H-PYRAZOL-4-YL)-7-(3,5- DIMETHYL-1,2-OXAZOL-4-YL)-8-METHOXY-5H-PYRIDO[4,3- B]INDOLE | 4z93 | A | P375 | III | Peptide ligand (ARG,THR,TYR,GLU,THR,PHE,LYS,SER,ILE,MET,LYS,LYS,SER) | 2lsp | B | P375 I393 | III | Peptide ligand (SER,PRO,ALA,GLN,GLY,LYS,ARG,GLY,LYS,LYS,SER,ALA) | 2mjv | B | P375 I393 M425 | III | Peptide ligand (SER,GLY,ARG,GLY,LYS,GLY,GLY,LYS,GLY,LEU,GLY,TYR) | 3uvw | A | P95 D96 | 1QK | DINACICLIB | 3-[({3-ETHYL-5-[(2S)-2-(2-HYDROXYETHYL)PIPERIDIN-1- YL]PYRAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)METHYL]-1- HYDROXYPYRIDINIUM | 4o70 | A | V90 |
Top |
Conservation information for LBS of BRD4 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |